Taysha Gene Therapies Inc logo

TSHA - Taysha Gene Therapies Inc Share Price

$20.02 -0.5  -2.6%

Last Trade - 23/10/20

Sector
Healthcare
Size
Mid Cap
Market Cap £567.9m
Enterprise Value £559.4m
Revenue £n/a
Position in Universe 2628th / 6447
Bullish
Bearish
Unlock TSHA Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -27.3%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Taysha Gene Therapies Inc revenues was not reported. Net loss totaled to $26.7M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

TSHA Revenue Unlock TSHA Revenue

Net Income

TSHA Net Income Unlock TSHA Revenue

Normalised EPS

TSHA Normalised EPS Unlock TSHA Revenue

PE Ratio Range

TSHA PE Ratio Range Unlock TSHA Revenue

Dividend Yield Range

TSHA Dividend Yield Range Unlock TSHA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
TSHA EPS Forecasts Unlock TSHA Revenue
Profile Summary

Taysha Gene Therapies, Inc. is a gene therapy company focused on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. Its product candidates include: TSHA-101, which is being developed for the treatment of GM2 gangliosidosis; TSHA-118, which is a AAV9 viral vector that expresses human codon-optimized Ceroid Lipofuscinosis Neuronal 1 complementary deoxyribonucleic acid under control of the chicken b-actin hybrid promoter; TSHA-102, which is being developed for the treatment of Rett syndrome; TSHA-103, which is being developed for the treatment of Solute Carrier Family 6 Member 1 (SLC6A1) haploinsufficiency disorder, and TSHA-104, which is being developed for the treatment for Surfeit locus 1.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
No. of Shareholders: n/a
No. of Employees: 10
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 36,992,409
Free Float (0.0%)
Eligible for
ISAs
SIPPs
TSHA Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for TSHA
Upcoming Events for TSHA
Frequently Asked Questions for Taysha Gene Therapies Inc
What is the Taysha Gene Therapies Inc share price?

As of 23/10/20, shares in Taysha Gene Therapies Inc are trading at $20.02, giving the company a market capitalisation of £567.9m. This share price information is delayed by 15 minutes.

How has the Taysha Gene Therapies Inc share price performed this year?

Shares in Taysha Gene Therapies Inc are currently trading at $20.02 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Taysha Gene Therapies Inc price has moved by % over the past year.

What are the analyst and broker recommendations for Taysha Gene Therapies Inc?

There are no analysts currently covering Taysha Gene Therapies Inc.

When will Taysha Gene Therapies Inc next release its financial results?

Taysha Gene Therapies Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Taysha Gene Therapies Inc dividend yield?

Taysha Gene Therapies Inc does not currently pay a dividend.

Does Taysha Gene Therapies Inc pay a dividend?

Taysha Gene Therapies Inc does not currently pay a dividend.

When does Taysha Gene Therapies Inc next pay dividends?

Taysha Gene Therapies Inc does not currently pay a dividend.

How do I buy Taysha Gene Therapies Inc shares?

To buy shares in Taysha Gene Therapies Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Taysha Gene Therapies Inc?

Shares in Taysha Gene Therapies Inc are currently trading at $20.02, giving the company a market capitalisation of £567.9m.

Where are Taysha Gene Therapies Inc shares listed? Where are Taysha Gene Therapies Inc shares listed?

Here are the trading details for Taysha Gene Therapies Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: TSHA
What kind of share is Taysha Gene Therapies Inc?

Based on an overall assessment of its quality, value and momentum, Taysha Gene Therapies Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Taysha Gene Therapies Inc share price forecast 2020?

We were not able to load any forecast data for Taysha Gene Therapies Inc.

How can I tell whether the Taysha Gene Therapies Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Taysha Gene Therapies Inc. Over the past six months, the relative strength of its shares against the market has been %. At the current price of $20.02, shares in Taysha Gene Therapies Inc are trading at -6.13% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Taysha Gene Therapies Inc PE Ratio?

We were not able to find PE ratio data for Taysha Gene Therapies Inc.

Who are the key directors of Taysha Gene Therapies Inc?

We were unable to find the directors for Taysha Gene Therapies Inc.

Who are the major shareholders of Taysha Gene Therapies Inc?

Here are the top five shareholders of Taysha Gene Therapies Inc based on the size of their shareholding:

Session (R. A. II) Individual Investor
Percentage owned: 25.49% (9.43m shares)
Manning (Paul B.) Individual Investor
Percentage owned: 14.31% (5.30m shares)
Southwestern Medical Foundation Foundation
Percentage owned: 5.89% (2.18m shares)
Prasad (Suyash) Individual Investor
Percentage owned: 1.82% (673k shares)
Alam (Kamran CPA) Individual Investor
Percentage owned: 0.9% (331k shares)
Similar to TSHA
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.